- Home
- DYAI vs NEUP Comparison
DYAI vs NEUP Comparison
Compare DYAI & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DYAI | NEUP |
|---|---|---|
| Founded | 1979 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0M | 14.9M |
| IPO Year | 2026 | 2002 |
Fundamental Metrics
Financial Performance| Metric | DYAI | NEUP |
|---|---|---|
| Price | $0.33 | $2.56 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 91.2K | 32.8K |
| Earning Date | 11-12-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,090,345.00 | $1,174,165.00 |
| Revenue This Year | $113.16 | N/A |
| Revenue Next Year | $94.92 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.33 | $2.54 |
| 52 Week High | $1.60 | $5.53 |
Technical Indicators
Market Signals| Indicator | DYAI | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 36.72 | 16.20 |
| Support Level | N/A | N/A |
| Resistance Level | $0.48 | $4.15 |
| Average True Range (ATR) | 0.04 | 0.14 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 8.59 | 2.11 |
Price Performance
Historical ComparisonAbout DYAI Dyadic International Inc.
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
About NEUP Neuphoria Therapeutics Inc.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company focused on therapies for serious central nervous system disorders. Its lead product candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor. The company has discontinued development of BNC210 for social anxiety disorder, while its BNC210 program for post-traumatic stress disorder is currently paused and no active clinical trial is underway. The company operates through a single operating and reporting segment focused on the discovery and development of allosteric ion-channel modulators for serious CNS disorders with high unmet medical need.